Cooler Heads Secures $11M: Revolutionizing Chemotherapy Patient Care
July 25, 2025, 9:35 am
Cooler Heads secured $11 million in Series A funding. This fuels the expansion of Amma, their FDA-cleared portable scalp cooling system. Amma prevents chemotherapy-induced hair loss. It offers a continuous, accessible solution. This investment boosts manufacturing. It expands market reach. It solidifies scalp cooling as a critical standard of cancer care. The innovation addresses a major patient concern. It improves treatment acceptance and quality of life for those undergoing chemotherapy.
Cooler Heads, a trailblazing medical device company, has secured a significant $11 million in Series A funding. This capital infusion propels the firm forward. It cements its position as a leader in patient-centric cancer care. The funding round saw robust participation. Mutual Capital Partners led the investment. SHD Partners, Crescent Ridge VC, and several other key investors joined the round. This financial boost targets a critical aspect of chemotherapy treatment. It addresses the devastating impact of hair loss.
Hair loss remains a profound side effect of chemotherapy. It causes immense emotional distress. Some patients even forgo life-saving treatment due to this fear. Cooler Heads directly confronts this challenge. Their flagship product is Amma. Amma is an FDA-cleared portable scalp cooling system. It offers a vital solution. It empowers patients to maintain dignity and privacy during cancer therapy.
Amma's technology is ingenious. It cools the scalp before, during, and after chemotherapy sessions. This cooling constricts blood vessels. It reduces blood flow to hair follicles. Chemotherapy drugs then bypass these protected areas. This prevents widespread hair loss. The system provides continuous cooling. This eliminates the need for cumbersome dry ice. It also removes the hassle of frequent cap changes. Amma offers flexibility. Patients can use it in infusion centers. They can also use it in other convenient locations. Its portability is a game-changer. It makes scalp cooling far more accessible than ever before.
The $11 million investment signals strong market confidence. It recognizes Amma’s potential. The funds will be strategically deployed. A major portion will expand manufacturing capacity. This ensures Amma reaches more patients nationwide. The company will also grow its commercial team. This team will drive product rollout. They will forge partnerships with healthcare providers. Furthermore, the investment supports research and development. Cooler Heads plans to develop the next generation of Amma. This commitment to innovation is unwavering.
Strategic appointments strengthen Cooler Heads' leadership. Liz Todia Zambory from Mutual Capital joins the board. Mike Schotzinger of SHD Partners also takes a board seat. Jason Pesterfield, CEO of Elucent Medical, joins as an independent director. These additions bring invaluable expertise. Their insights will guide Cooler Heads through its next phase of growth. They will help scale operations and market penetration.
The medical community increasingly recognizes scalp cooling’s importance. The American Medical Association (AMA) has taken a decisive step. They will elevate scalp cooling reimbursement codes to Category I. This change takes effect in January 2026. It marks a pivotal moment. Category I status solidifies scalp cooling as an emerging standard of care. This decision provides powerful momentum for Cooler Heads. It ensures broader insurance coverage. It makes Amma more affordable for patients. This regulatory shift is transformative for patient access.
Cooler Heads is not just a medical device company. It is a champion for cancer patients. The company provides evidence-based products. It offers valuable content and services. These resources help patients manage challenging treatment side effects. Amma epitomizes this holistic approach. It addresses a significant physical and emotional burden. It allows patients to focus on healing. It restores a sense of normalcy during a difficult time.
The market demand for effective scalp cooling solutions is substantial. Many cancer patients prioritize minimizing treatment side effects. Hair loss is often cited as the most distressing. Amma’s discreet nature and ease of use set it apart. It integrates seamlessly into existing infusion center workflows. This low-friction implementation benefits both patients and clinics. Infusion centers can easily offer this vital therapy.
Cooler Heads is poised for significant impact. Their technology offers hope. It provides comfort. It restores confidence for countless individuals undergoing chemotherapy. This $11 million funding round is more than just a financial milestone. It is a testament to Amma’s transformative power. It underscores the growing recognition of scalp cooling as an essential component of comprehensive cancer care. The future of patient experience in oncology looks brighter. Cooler Heads is leading that charge. They are redefining what is possible in supportive cancer therapy. Their portable system provides flexibility and empowers patients globally. This innovation reduces suffering. It enhances lives. It reshapes the journey through cancer treatment.
Cooler Heads, a trailblazing medical device company, has secured a significant $11 million in Series A funding. This capital infusion propels the firm forward. It cements its position as a leader in patient-centric cancer care. The funding round saw robust participation. Mutual Capital Partners led the investment. SHD Partners, Crescent Ridge VC, and several other key investors joined the round. This financial boost targets a critical aspect of chemotherapy treatment. It addresses the devastating impact of hair loss.
Hair loss remains a profound side effect of chemotherapy. It causes immense emotional distress. Some patients even forgo life-saving treatment due to this fear. Cooler Heads directly confronts this challenge. Their flagship product is Amma. Amma is an FDA-cleared portable scalp cooling system. It offers a vital solution. It empowers patients to maintain dignity and privacy during cancer therapy.
Amma's technology is ingenious. It cools the scalp before, during, and after chemotherapy sessions. This cooling constricts blood vessels. It reduces blood flow to hair follicles. Chemotherapy drugs then bypass these protected areas. This prevents widespread hair loss. The system provides continuous cooling. This eliminates the need for cumbersome dry ice. It also removes the hassle of frequent cap changes. Amma offers flexibility. Patients can use it in infusion centers. They can also use it in other convenient locations. Its portability is a game-changer. It makes scalp cooling far more accessible than ever before.
The $11 million investment signals strong market confidence. It recognizes Amma’s potential. The funds will be strategically deployed. A major portion will expand manufacturing capacity. This ensures Amma reaches more patients nationwide. The company will also grow its commercial team. This team will drive product rollout. They will forge partnerships with healthcare providers. Furthermore, the investment supports research and development. Cooler Heads plans to develop the next generation of Amma. This commitment to innovation is unwavering.
Strategic appointments strengthen Cooler Heads' leadership. Liz Todia Zambory from Mutual Capital joins the board. Mike Schotzinger of SHD Partners also takes a board seat. Jason Pesterfield, CEO of Elucent Medical, joins as an independent director. These additions bring invaluable expertise. Their insights will guide Cooler Heads through its next phase of growth. They will help scale operations and market penetration.
The medical community increasingly recognizes scalp cooling’s importance. The American Medical Association (AMA) has taken a decisive step. They will elevate scalp cooling reimbursement codes to Category I. This change takes effect in January 2026. It marks a pivotal moment. Category I status solidifies scalp cooling as an emerging standard of care. This decision provides powerful momentum for Cooler Heads. It ensures broader insurance coverage. It makes Amma more affordable for patients. This regulatory shift is transformative for patient access.
Cooler Heads is not just a medical device company. It is a champion for cancer patients. The company provides evidence-based products. It offers valuable content and services. These resources help patients manage challenging treatment side effects. Amma epitomizes this holistic approach. It addresses a significant physical and emotional burden. It allows patients to focus on healing. It restores a sense of normalcy during a difficult time.
The market demand for effective scalp cooling solutions is substantial. Many cancer patients prioritize minimizing treatment side effects. Hair loss is often cited as the most distressing. Amma’s discreet nature and ease of use set it apart. It integrates seamlessly into existing infusion center workflows. This low-friction implementation benefits both patients and clinics. Infusion centers can easily offer this vital therapy.
Cooler Heads is poised for significant impact. Their technology offers hope. It provides comfort. It restores confidence for countless individuals undergoing chemotherapy. This $11 million funding round is more than just a financial milestone. It is a testament to Amma’s transformative power. It underscores the growing recognition of scalp cooling as an essential component of comprehensive cancer care. The future of patient experience in oncology looks brighter. Cooler Heads is leading that charge. They are redefining what is possible in supportive cancer therapy. Their portable system provides flexibility and empowers patients globally. This innovation reduces suffering. It enhances lives. It reshapes the journey through cancer treatment.